EQRx, Inc. entered into memorandum of understanding (MOU) with CVS Health. The companies plan to explore a long-term, strategic partnership to accelerate the commercial availability of lower-cost specialty therapeutics and create cost savings for CVS Health clients, patients and members through the adoption of EQRx medicines granted approval by the U.S. Food & Drug Administration (FDA). Initially, the companies plan to work together to support access to and adoption of EQRx's two lead oncology products, contingent upon FDA approval.

EQRx and CVS Health will also explore opportunities for collaboration in support of their mutually aligned goal of bringing other innovative, lower-cost specialty medications to market in order to significantly reduce overall drug spend.